Adimab

Executive Summary

Adimab is a privately-held biotechnology company based in Lebanon, New Hampshire, that has established itself as a leading provider of antibody discovery and engineering services since its founding in 2007. The company's proprietary yeast-based platform enables the rapid and efficient development of therapeutic antibodies with high specificity, stability, and developability, including IgG, HCAb, multispecific, and TCR formats. Adimab operates on a pure-play services model, generating revenue through partnerships with pharmaceutical and biotech companies, and does not maintain an internal drug pipeline. This business model has allowed Adimab to collaborate with over 50 partners, contributing to numerous clinical-stage programs without the capital intensity and risk of internal drug development. Given its track record and broad platform capabilities, Adimab is well-positioned to continue benefiting from the growing demand for outsourced antibody discovery and engineering, particularly as the industry increasingly turns to complex formats like bispecifics and multispecifics.

Upcoming Catalysts (preview)

• Q3 2026Major pharma partnership announcement75% success
• Q4 2026Expansion of platform capabilities into new therapeutic modalities (e.g., cell engagers, protein degraders)60% success
• Q2 2026Potential initial public offering (IPO) or significant financing round40% success